Interní Med. 2019; 21(4): 212-216 | DOI: 10.36290/int.2019.032

Treatment of gout and hyperuricemia

doc. MUDr. Petr Bradna, CSc.
II. interní gastroenterologická klinika, Subkatedra revmatologie FN a LF UK Hradec Králové

Gout is the most common inflammatory arthritis in adult populations. Its prevalence is growing, especially in developed countries. Gouty arthritis is a extremely painful disease severely affecting the quality of life and with its relationship to cardiovascular risks gout is also life-threatening disease. In recent times has changed the paradigm of the treatment of acute gouty arthritis and also long- term hypouricemic therapy. An important place in the complex treatment plays non-pharmacological treatment, which include not just a diet, but also other aspects of lifestyle (exercise, overweight). Complex therapy of gout must contain also control of systemic risks of the disease.

Keywords: hyperuricemia, treatment, atherogenesis, dementia

Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bradna P. Treatment of gout and hyperuricemia. Interní Med. 2019;21(4):212-216. doi: 10.36290/int.2019.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases.Proc Natl Acad Sci U S A. 2014; 111(10): 3763-3768. doi: 10.1073/pnas.1320393111. Go to original source... Go to PubMed...
    2. Tan PK, Farrar JE, Gaucher JA, et al. Coevolution of URAT1 and Uricase during Primate Evolution:Implications for Serum Urate Homeostasis and Gout Mol. Biol. Evol. 33(9):2193-2200 doi:10.1093/molbev/msw116. Go to original source... Go to PubMed...
    3. Kuo CH.F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nature Reviews Rheumatology volume11, pages649-662 (2015) Go to original source... Go to PubMed...
    4. Elfishawi MT, Zleik N, Kvrgic Z. The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-Based Study Over 20 Years. J Rheumatol. 2018 April; 45(4): 574-579. doi:10.3899/ Go to original source... Go to PubMed...
    5. Dehlin M, Drivelegka P, Sigurdardotti V, et al. Incidence and prevalence of gout in western Sweden. Arthritis Research Therapy 2016; 18:164-171 DOI 10.1186/s13075-016-1062-6. Go to original source... Go to PubMed...
    6. Závada J, Pavelka K. Dnavá artritida. In: Pavelka K a kol. Revmatologie Maxdorf Praha 2018: 536-554.
    7. Kumar AU, Browne LD, Li X. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study PLOS ONE, https://doi.org/10.1371/journal.pone.0198197 May 31, 2018.
    8. Pavlík V, Fajfrová J, Šafka V, et al. Prevalence of risk factors in cardiovascular diseases in selected population of the Czech Republic. Cent Eur J Public Health 2018; 26 (2): 118-123. Go to original source... Go to PubMed...
    9. Lee SK, Jung JY, Jee WH, et al. Combining non-contrast and dual-energy CT improves diagnosis of early gout. Eur Radiol. 2019; 29:1267-1275. doi: 10.1007/s00330-018-5716-4. Go to original source... Go to PubMed...
    10. Richette P,Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis Epub ahead of print: 5 June 2019. doi:10.1136/annrheumdis-2019-215315.
    11. Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout Ann Rheum, DiS. 2017;76:632-638 doi: 10.1136/annrheumdis-2016-209467. Go to original source... Go to PubMed...
    12. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42 doi:10.1136/annrheumdis-2016-209707. Go to original source... Go to PubMed...
    13. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for Management of Gout.Part 1-2 Arthritis Care Res (Hoboken). 2012; 64: 1431-1461. Go to original source... Go to PubMed...
    14. Pavelka K. Doporučení České revmatologické společnosti pro léčbu dnavé artritidy. Čes. Revmatol. 2012; 20: 82-92.
    15. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004; 363: 1277-1281. Go to original source... Go to PubMed...
    16. Neoghi T, Chen C, Niu J, et al. Alcohol quantity and type on risk of recurrent gout attacks: An internet-based case-crossover study. Am J Med. 2014; 127: 311-318. doi:10.1016/j.amjmed.2013.12.019. Go to original source... Go to PubMed...
    17. Pontremoli R. The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies. Current Medical Research and Opinion, 2017; 33:sup3, 27-32, DOI: 10.1080/03007995.2017.1378523. Go to original source... Go to PubMed...
    18. Bredemeier M, Moreira Lopes M, Eisenreich MA, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematicreview and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018; 18: 24-35. doi: 10.1186/s12872-018-0757-9. Go to original source... Go to PubMed...
    19. Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol 2017; 36:2637-2644. DOI 10.1007/s10067-017-3851-y Go to original source... Go to PubMed...
    20. Scheepers LE, Jacobsson LTH, Kern S. Urate and risk of Alzheimer's disease and vascular dementia: A population-based study. Alzheimers Dement. 2019 May 2. pii: S1552-5260(19)30046-9. doi: 10.1016/j.jalz.2019. 01. 014. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.